CDK5 and hepatocellular carcinoma: CDK5 deficiency in hepatocellular carcinoma (HCC) cells upregulates PD-L1 through decreased phosphorylation and reduced chaperone-mediated autophagy, enhancing response to anti-PD-1 immunotherapy and improving survival in HCC-bearing mice.